comparemela.com

Page 4 - Xuhui Plant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fosun International : First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients

First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients . | June 16, 2023

United statesYi nanUnited kingdomNorihiro kokudoc gunnar folprechtdRobertp jonesaShanghai henlius biotech incJournal of the american medical associationEuropean unionNational medical products administrationHenlius biotechAmerican medical associationNature medicineBritish journalSmall cell lung cancerNon small cell lung cancerEsophageal cancer

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged

/PRNewswire/ As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals.

United kingdomUnited statesSaudi arabiaEuropean medicines agencyEuropean commissionDrug administrationSongjiang first plantBiologics license applicationMarketing authorization applicationGood manufacturing practiceXuhui plant

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3 2 Billion in Revenues

/PRNewswire/ Henlius (2696.HK) announced its 2022 annual results. In 2022, Henlius revenue reached about RMB3.2147 billion, representing an increase of.

United kingdomSaudi arabiaWenjie zhangGetz pharmaFosun pharmaNovacyte therapeutics biomedical technologyDrug administrationEuropean commissionEuropean medicines agencyExecutive directorChief executive officerBiologics license applicationMarketing authorization applicationNew drugNature medicineMedilink therapeutics

Henlius Announces U S FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License.

United statesUnited kingdomSaudi arabiaJason zhuPrnewswire shanghai henlius biotech incJacobson groupAccord biopharma incEuropean commissionDrug administrationIntas pharmaceuticals ltdEuropean medicines agencyNational medical products administrationHenlius biotechBiologics license applicationAccord biopharmaXuhui facility

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ Fosun Pharma has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. for the commercialisation of Henlius. | January 7, 2023

United statesKrong yangWenjie zhangPrnewswire fosun pharmaWu yifangFosun pharmaInternational good manufacturing practiceSinopharm co ltdShanghai fosun pharmaceutical group co ltdFosun pharma united states incShanghai henlius biotech incEuropean unionEuropean medicines agencyShanghai henlius biotechSenior vice presidentFosun pharma united states

vimarsana © 2020. All Rights Reserved.